Literature DB >> 22878649

MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.

Nicolai A Schultz1, Jens Werner, Hanni Willenbrock, Anne Roslind, Nathalia Giese, Thomas Horn, Morten Wøjdemann, Julia S Johansen.   

Abstract

MicroRNAs have potential as diagnostic cancer biomarkers. The aim of this study was (1) to define microRNA expression patterns in formalin-fixed parafin-embedded tissue from pancreatic ductal adenocarcinoma, ampullary adenocarcinoma, normal pancreas and chronic pancreatitis without using micro-dissection and (2) to discover new diagnostic microRNAs and combinations of microRNAs in cancer tissue. The expression of 664 microRNAs in tissue from 170 pancreatic adenocarcinomas and 107 ampullary adenocarcinomas were analyzed using a commercial microRNA assay. Results were compared with chronic pancreatitis, normal pancreas and duodenal adenocarcinoma. In all, 43 microRNAs had higher and 41 microRNAs reduced expression in pancreatic cancer compared with normal pancreas. In all, 32 microRNAs were differently expressed in pancreatic adenocarcinoma compared with chronic pancreatitis (17 higher; 15 reduced). Several of these microRNAs have not before been related to diagnosis of pancreatic cancer (eg, miR-492, miR-614, miR-622). MiR-614, miR-492, miR-622, miR-135b and miR-196 were most differently expressed. MicroRNA profiles of pancreatic and ampullary adenocarcinomas were correlated (0.990). MicroRNA expression profiles for pancreatic cancer described in the literature were consistent with our findings, and the microRNA profile for pancreatic adenocarcinoma (miR-196b-miR-217) was validated. We identified a more significant expression profile, the difference between miR-411 and miR-198 (P=2.06 × 10(-54)) and a diagnostic LASSO classifier using 19 microRNAs (sensitivity 98.5%; positive predictive value 97.8%; accuracy 97.0%). We also identified microRNA profiles to subclassify ampullary adenocarcinomas into pancreatobiliary or intestinal type. In conclusion, we found that combinations of two microRNAs could roughly separate neoplastic from non-neoplastic samples. A diagnostic 19 microRNA classifier was constructed which without micro-dissection could discriminate pancreatic and ampullary adenocarcinomas from chronic pancreatitis and normal pancreas with high sensitivity and accuracy. Ongoing prospective studies will evaluate if these microRNA profiles are useful on fine-needle biopsies for early diagnosis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878649     DOI: 10.1038/modpathol.2012.122

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  76 in total

1.  Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer.

Authors:  Mao-Song Lin; Wei-Chang Chen; Jun-Xing Huang; Heng-Jun Gao; Hai-Hui Sheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Ampullary cancer: an overview.

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Authors:  Weihua Chang; Menggang Liu; Jianhua Xu; Hangwei Fu; Bo Zhou; Tao Yuan; Ping Chen
Journal:  Tumour Biol       Date:  2016-09-16

4.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

5.  MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles.

Authors:  Zhongyang Ding; Haorong Wu; Jiaming Zhang; Guorong Huang; Dongdong Ji
Journal:  Tumour Biol       Date:  2014-06-02

6.  miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.

Authors:  F Lahdaoui; Y Delpu; A Vincent; F Renaud; M Messager; B Duchêne; E Leteurtre; C Mariette; J Torrisani; N Jonckheere; I Van Seuningen
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

7.  microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma.

Authors:  Wei-Hua Song; Xiao-Jun Feng; Shao-Juan Gong; Jian-Ming Chen; Shou-Mei Wang; Dong-Juan Xing; Ming-Hua Zhu; Shu-Hui Zhang; Ai-Min Xu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

9.  miR-301a expression: A prognostic marker for prostate cancer.

Authors:  Chendil Damodaran; Trinath P Das; A M Sashi Papu John; Suman Suman; Venkatesh Kolluru; Targhee J Morris; Erin N Faber; Shesh N Rai; Jamie C Messer; Houda Alatassi; Murali K Ankem
Journal:  Urol Oncol       Date:  2016-04-26       Impact factor: 3.498

10.  Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma.

Authors:  Xinzhi Wang; Zhenxue Xin; Yinfu Xu; Jinbang Ma
Journal:  Tumour Biol       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.